EGFR and head and neck squamous cell carcinoma: Further research is needed to elucidate the molecular mechanisms underlying the response to EGFR-inhibition in HNSCC and to characterize biomarkers which would allow for the identification of individuals who are likely to benefit from EGFR-targeting strategies as well as for the development of more effective mono- and combinatorial therapeutic approaches for the treatment of HNSCC.